Isabl
4 known investors
Isabl develops genomic sequencing technology for cancer diagnosis, enabling whole genome and transcriptome testing in clinically relevant timeframes to provide comprehensive treatment options. The platform serves physicians and cancer patients globally by making advanced molecular diagnostics accessible.